These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12866577)

  • 1. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
    Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
    J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
    Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
    Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
    Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
    Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
    Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
    Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
    Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
    Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
    Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
    Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
    Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
    Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
    J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS; Wang Y; Tull J; Zhang S
    Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.
    Lal P; Salazar PA; Ladanyi M; Chen B
    J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.